Status:
COMPLETED
LUMINIST: LUng Cancer Molecular Insights Non Interventional Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Quintiles, Inc.
Conditions:
NSCLC
Eligibility:
All Genders
Brief Summary
The recent development of therapies targeting specific biomarkers mutations is changing the standards of care and prognosis of patients with advanced NSCLC, but very few data are currently available o...
Detailed Description
The LUMINIST study will enrol patients who are ineligible for the SELECT-1 (NCT01933932) or SELECT-2 (NCT01750281)RCTs. Within this NIS patients will be followed longitudinally for treatment informati...
Eligibility Criteria
Inclusion
- Provision of informed consent from the patient or next-of-kin for deceased patient at study entry, where this is mandated by local regulations
- Female and male adults (according to each country regulations for age of majority)
- Patients who are not eligible or choose not to enter selumetinib SELECT-1 or SELECT-2 trials
- Patients with confirmed histological diagnosis of NSCLC
Exclusion
- 1\. Involved in the planning and/or conduct of this study (applies to both AZ staff and/or staff at the study site)
Key Trial Info
Start Date :
December 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2016
Estimated Enrollment :
770 Patients enrolled
Trial Details
Trial ID
NCT02300831
Start Date
December 1 2014
End Date
June 30 2016
Last Update
July 14 2017
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Camperdown, Australia
2
Research Site
Darlinghurst, Australia
3
Research Site
Kurralta Park, Australia
4
Research Site
Wendouree, Australia